Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Georg Schett

Showing results (861-870 of 908) with videos related to

Pageof 91
Sort By:
Nature Communications|April 26, 2020
Targeting zonulin and intestinal epithelial barrier function to prevent onset of arthritisNarges Tajik, Michael Frech, Oscar Schulz, et al.
Nature Medicine|July 18, 2017
Resolution of inflammation by interleukin-9-producing type 2 innate lymphoid cellsSimon Rauber, Markus Luber, Stefanie Weber, et al.
Annals of the Rheumatic Diseases|May 26, 2021
Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory diseaseRebecca H Haberman, Ramin Herati, David Simon, et al.
The Lancet. Rheumatology|February 1, 2024
Treatment tapering and stopping in patients with rheumatoid arthritis in stable remission (RETRO): a multicentre, randomised, controlled, open-label, phase 3 trialKoray Tascilar, Melanie Hagen, Arnd Kleyer, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 24, 2021
Impact of Cytokine Inhibitor Therapy on the Prevalence, Seroconversion Rate, and Longevity of the Humoral Immune Response Against SARS-CoV-2 in an Unvaccinated CohortDavid Simon, Koray Tascilar, Arnd Kleyer, et al.
Annals of the Rheumatic Diseases|July 12, 2025
Effects of different B-cell-depleting strategies on the lymphatic tissueCarlo Tur, Markus Eckstein, Laura Bucci, et al.
Nature Communications|July 26, 2020
Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversionDavid Simon, Koray Tascilar, Gerhard Krönke, et al.
BMJ Open|January 8, 2025
Paucity of viral infection symptoms in patients with immune-mediated inflammatory diseasesMelek Yalcin Mutlu, Arnd Kleyer, Gerhard Kroenke, et al.
Journal of Clinical Medicine|June 10, 2023
Physical Function of RA patients Tapering Treatment-A Post Hoc Analysis of the Randomized Controlled RETRO TrialMarlene Stephan, Koray Tascilar, Melek Yalcin-Mutlu, et al.
Nature Communications|February 19, 2021
Interleukin-3 is a predictive marker for severity and outcome during SARS-CoV-2 infectionsAlan Bénard, Anne Jacobsen, Maximilian Brunner, et al.
Pageof 91

Showing results (861-870 of 908) with videos related to

Sort By:
Pageof 91
Nature Communications|April 26, 2020
Targeting zonulin and intestinal epithelial barrier function to prevent onset of arthritisNarges Tajik, Michael Frech, Oscar Schulz, et al.
Nature Medicine|July 18, 2017
Resolution of inflammation by interleukin-9-producing type 2 innate lymphoid cellsSimon Rauber, Markus Luber, Stefanie Weber, et al.
Annals of the Rheumatic Diseases|May 26, 2021
Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory diseaseRebecca H Haberman, Ramin Herati, David Simon, et al.
The Lancet. Rheumatology|February 1, 2024
Treatment tapering and stopping in patients with rheumatoid arthritis in stable remission (RETRO): a multicentre, randomised, controlled, open-label, phase 3 trialKoray Tascilar, Melanie Hagen, Arnd Kleyer, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 24, 2021
Impact of Cytokine Inhibitor Therapy on the Prevalence, Seroconversion Rate, and Longevity of the Humoral Immune Response Against SARS-CoV-2 in an Unvaccinated CohortDavid Simon, Koray Tascilar, Arnd Kleyer, et al.
Annals of the Rheumatic Diseases|July 12, 2025
Effects of different B-cell-depleting strategies on the lymphatic tissueCarlo Tur, Markus Eckstein, Laura Bucci, et al.
Nature Communications|July 26, 2020
Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversionDavid Simon, Koray Tascilar, Gerhard Krönke, et al.
BMJ Open|January 8, 2025
Paucity of viral infection symptoms in patients with immune-mediated inflammatory diseasesMelek Yalcin Mutlu, Arnd Kleyer, Gerhard Kroenke, et al.
Journal of Clinical Medicine|June 10, 2023
Physical Function of RA patients Tapering Treatment-A Post Hoc Analysis of the Randomized Controlled RETRO TrialMarlene Stephan, Koray Tascilar, Melek Yalcin-Mutlu, et al.
Nature Communications|February 19, 2021
Interleukin-3 is a predictive marker for severity and outcome during SARS-CoV-2 infectionsAlan Bénard, Anne Jacobsen, Maximilian Brunner, et al.
Pageof 91